C WorldWide Group Holding A S Has $5.49 Million Stake in Insulet Corporation (NASDAQ:PODD)

C WorldWide Group Holding A S increased its stake in Insulet Corporation (NASDAQ:PODD) by 19.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 107,065 shares of the medical instruments supplier’s stock after buying an additional 17,644 shares during the period. C WorldWide Group Holding A S owned 0.18% of Insulet Corporation worth $5,494,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of PODD. Granite Investment Partners LLC increased its position in Insulet Corporation by 0.4% in the second quarter. Granite Investment Partners LLC now owns 19,502 shares of the medical instruments supplier’s stock valued at $1,001,000 after buying an additional 76 shares during the period. Schwab Charles Investment Management Inc. increased its position in Insulet Corporation by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 252,670 shares of the medical instruments supplier’s stock valued at $12,965,000 after buying an additional 8,399 shares during the period. Lebenthal Lisanti Capital Growth LLC bought a new position in Insulet Corporation during the second quarter valued at approximately $799,000. Kornitzer Capital Management Inc. KS increased its position in Insulet Corporation by 1.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 280,760 shares of the medical instruments supplier’s stock valued at $14,406,000 after buying an additional 3,260 shares during the period. Finally, Strs Ohio increased its position in Insulet Corporation by 35.0% in the second quarter. Strs Ohio now owns 5,400 shares of the medical instruments supplier’s stock valued at $277,000 after buying an additional 1,400 shares during the period.

Shares of Insulet Corporation (NASDAQ:PODD) opened at 52.53 on Friday. The firm’s market capitalization is $3.05 billion. The company’s 50 day moving average price is $51.17 and its 200-day moving average price is $45.07. Insulet Corporation has a 52 week low of $30.69 and a 52 week high of $55.46.

Insulet Corporation (NASDAQ:PODD) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $110 million during the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. Insulet Corporation’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period last year, the company earned ($0.08) EPS. On average, equities research analysts expect that Insulet Corporation will post ($0.51) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/08/11/c-worldwide-group-holding-a-s-has-5-49-million-stake-in-insulet-corporation-nasdaqpodd.html.

Several equities analysts recently commented on the company. Jefferies Group LLC restated a “buy” rating and set a $58.00 target price (up previously from $48.00) on shares of Insulet Corporation in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $55.00 target price on Insulet Corporation and gave the stock a “hold” rating in a research report on Friday, August 4th. Northland Securities restated a “buy” rating on shares of Insulet Corporation in a research report on Friday, August 4th. Cowen and Company restated an “outperform” rating and set a $63.00 target price (up previously from $52.00) on shares of Insulet Corporation in a research report on Friday, August 4th. Finally, BidaskClub downgraded Insulet Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 1st. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $50.46.

In related news, SVP Michael P. Spears bought 2,500 shares of the stock in a transaction that occurred on Tuesday, May 16th. The stock was acquired at an average cost of $40.59 per share, with a total value of $101,475.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by company insiders.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

What are top analysts saying about Insulet Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Insulet Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit